Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
Status:
Recruiting
Trial end date:
2023-08-12
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of short-term fasting in patients with skin
malignancy that has spread to other places in the body (advanced or metastatic) treated with
a PD-L1 or PD-1 inhibitor. Immunotherapy with monoclonal antibodies, such as pembrolizumab,
nivolumab, cemiplimab, avelumab, atezolizumab, or durvalumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Undergoing short-term fasting prior to treatment with one of these PD-L1 or PD-1
inhibitors may potentially reduce the side effects of immunotherapy or even improve the
effectiveness of immunotherapy in patients with skin malignancy.